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BACKGROUND : Paradoxical reactions in tuberculosis
(TB) are a notable example of our incomplete under-
standing of host-pathogen interactions during anti-
tuberculosis treatment.
OB J E C T I V E S : To determine risk factors for a TB
paradoxical reaction, and specifically to assess for an
independent association with vitamin D use.
DE S I GN : Consecutive human immunodeficiency virus
(HIV) negative adult patients treated for extra-pulmo-
nary TB were identified from an Extended Surveillance
of Mycobacterial Infections database. In our setting,
vitamin D was variably prescribed for newly diagnosed
TB patients. A previously published definition of
paradoxical TB reaction was retrospectively applied
to, and data on all previously described risk factors were
extracted from, centralised electronic patient records.
The association with vitamin D use was assessed using
multivariate logistic regression.
R E SU LT S : Of the 249 patients included, most had TB
adenopathy; 222/249 had microbiologically and/or
histologically confirmed TB. Vitamin D was prescribed
for 57/249 (23%) patients; 37/249 (15%) were classi-
fied as having paradoxical reactions. Younger age, acid-
fast bacilli-positive invasive samples, multiple disease
sites, lower lymphocyte count and vitamin D use were
found to be independent risk factors.
CONC LU S I ON : We speculate that vitamin D-mediated
signalling of pro-inflammatory innate immune cells,
along with high antigenic load, may mediate paradox-
ical reactions in anti-tuberculosis treatment.
K E Y WORD S : host-directed therapy; innate immunity;
host–pathogen interaction; inflammation
WORSENING OF TUBERCULOSIS (TB) disease
despite receipt of effective anti-tuberculosis treatment
is referred to as a ‘paradoxical upgrading reaction’
(PUR). A PUR is a clinical diagnosis based on
worsening of an existing TB lesion or development
of newly apparent TB lesions, which are typically
culture-negative and not associated with treatment
failure.1–7 PURs are most frequently diagnosed at
extra-pulmonary sites, where they can cause signifi-
cant morbidity. In addition, imaging modalities such
as positron emission tomography-computed tomog-
raphy reveal that most pulmonary TB (PTB) patients
have new lesions or lesions with increased metabolic
activity after 6 months of anti-tuberculosis treatment
despite sputum culture conversion.8 Similar rates of
new, subclinical lesions are seen on serial magnetic
resonance imaging of the brains of patients after
receipt of treatment for central nervous system TB.9
Rather than being an unusual event, PURs may be an
underappreciated central feature of the interaction
between Mycobacterium tuberculosis, host immunity
and antimicrobial treatment.
Historically, PURs have been thought to be
analogous to ‘upgrading reactions’ in leprosy.10 More
recently, TB PUR in the context of human immuno-
deficiency virus (HIV) associated immune reconstitu-
tion inflammatory syndrome (TB-IRIS) has been
described. Pathogenesis of antiretroviral treatment-
associated IRIS is increasingly understood to involve
innate immune mediators, including Toll-like recep-
tor (TLR) signalling.11
How a PUR might develop in the absence of overt
reversal of immune suppression as observed in HIV-
associated IRIS is not clear. A small number of studies
have indicated extra-pulmonary TB (EPTB), baseline
lymphopaenia and increased peripheral lymphocyte
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reconstitution to be risk factors in non-HIV-infected
TB patients.12,13 Vitamin D is a known immune
modulator in TB infection,14 and vitamin D deficien-
cy has been associated with PURs in some case
reports.13 No studies have assessed vitamin D
supplementation as a modulator of PUR risk. A
randomised control trial of high-dose vitamin D
supplementation during the intensive phase of PTB
treatment reported a PUR in 2/71 in the intervention
group and 0/70 in the placebo group—a non-
significant difference.15 However, that study had 56
days of follow-up (less than the median time to a PUR
in most studies) and was not powered to detect PUR
outcomes. A potential association between use of
vitamin D and PURs is therefore a pressing but open
question.16
Prescription of vitamin D is increasingly common
practice in TB clinics in our setting. This gave us an
opportunity to carry out a retrospective cohort study
to examine the effect of vitamin D use on the risk of
symptomatic PURs in patients treated for EPTB.
METHODS
Patients treated for EPTB at four hospitals collective-
ly responsible for .95% of TB management in the
Greater Glasgow and Clyde area of Scotland were
included in a retrospective cohort. In this setting,
vitamin D was prescribed ad hoc such that patients
received vitamin D at the discretion of individual
treating clinicians. Included were all consecutive
patients who: 1) were aged 718 years; 2) had
standard therapy for confirmed EPTB (culture-
positive or positive acid-fast bacilli [AFB] histology
or smear) or probable EPTB (clinical, histological or
radiological evidence of TB with response to anti-
tuberculosis treatment); and 3) were HIV-negative.
Patients already prescribed vitamin D before the
diagnosis of TB, and those with ,3 months of
recorded follow-up, were excluded.
Patients were identified from an Extended Surveil-
lance of Mycobacterial Infections database to which
all TB cases in Glasgow are notified. Demographic
and clinical data were obtained from centralised
electronic patient records and patient folders as
necessary. Independent variables collected included
all previously published risk factors for a PUR, and
any prescription of a vitamin D supplement during
TB treatment as a binary variable (for variable
definitions and prior literature review, see the
Appendix).* This retrospective review of routinely
collected data was exempted from formal ethics
review.
A published definition of a PUR1 (‘worsening of
pre-existing tuberculous lesions on the basis of
clinical or radiological findings or development of
new TB lesions in patients who had received anti-
tuberculosis treatment for at least 10 days and whose
conditions were reported to be improving’) was
retrospectively applied to all cases by two consultants
in infectious diseases (RAS and DJB) blinded to each
other’s assessment and the status of vitamin D
prescription. In cases of disagreement, a third
independent application of the case definition
(DAB) was used to break ties.
Assuming vitamin D was prescribed in 50% of
EPTB patients with an overall PUR prevalence of
18%, a sample size of 250 patients was calculated to
give 0.80 power at a¼0.05 to detect a 12% absolute
increase in PURs associated with vitamin D use.
Pairwise comparison of variables was by Fisher’s
exact test for categorical variables, and Wilcoxon’s
rank-sum test for non-normal numerical variables.
The association of vitamin D use with a PUR after
adjustment for variables thought to be potential
confounders was assessed by logistic regression. All
statistical analyses were carried out in R Studio
v0.99.902 (R Computing, Vienna, Austria); R code to
reproduce this analysis is available at https://github.
com/davidadambarr/PUR.EPTB.VitD.
RESULTS
Description of cohort
Of 260 patients included, 249 were assessed; 11 were
excluded due to evidence of vitamin D prescription
before a TB diagnosis (n¼5) or due to ,3 months of
recorded follow-up (n ¼ 6). Basic demographic and
clinical descriptors are shown in Table 1. Most
patients were of South Asian ethnicity; lymph nodes
were the most common site of disease. Invasive
diagnostic sampling (e.g., biopsy or aspiration) was
attempted in 230 patients (92%): 153/230 (67%)
were M. tuberculosis culture-positive; 69/230 (30%)
were culture-negative but AFB-positive or had
histological features in keeping with TB disease.
Of the 93 patients (37%) who had a baseline serum
level of 25-hydroxycholecalciferol checked, 45/93
(48%) had levels below the limit of detection for the
assay (,7 nmol/l, range ,7 to 114 nmol/l). Vitamin
D was prescribed for 57 patients (23%), not
necessarily according to baseline status, because not
all patients prescribed vitamin D had a baseline level
checked. For 52 (91%) of these patients, a dose
equivalent to 6800 international units (IU) of
colecalciferol per day was used, and 5/57 (9%)
received a one-off dose of 300 000 IU, followed by
20 000 IU monthly. Prescription of vitamin D differed
according to patient ethnicity, the clinic at which TB
was being treated, and by the baseline level of vitamin
D, although vitamin D deficiency was also prevalent
among patients not prescribed vitamin D (Table 1).
* The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2017/
00000021/00000006/art00013
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Thirty-seven patients (15%) were classified as
having a PUR. Inter-rater agreement was high for
the two primary assessors (Cohen’s j 0.84; 95%
confidence interval [CI] 0.74–0.94). The time of the
first PUR after starting anti-tuberculosis treatment
had a positively skewed distribution (median 52
[range 10–500] days). Corticosteroid treatment was
prescribed for 14/37 (38%) patients after a PUR; 5/37
(14%) had percutaneous drainage; 12/37 required no
specific treatment; and one patient had surgical
intervention for constrictive pericarditis associated
with a PUR.
Of 249 patients, 241 (97%) had a recorded
outcome available at the end of the treatment: 239/
241 (99%) were recorded as ‘clinically cured’, the
remaining two died on treatment (neither thought to
be related to a PUR). A median post-treatment
follow-up of 12 months was recorded; 3/239 (1%)
patients had recorded recurrent/relapsed TB at
respectively 2, 4 and 24 months after the end of
treatment.
Table 1 Description of cohort
Overall
(n ¼ 249)
Vitamin D not prescribed
(n ¼ 192)
Vitamin D prescribed
(n ¼ 57) P value*
Age, years, median [IQR] 36 [28.9–50.7] 38.7 [29.5–52.3] 32.7 [26.8–43.4] 0.055
Female 91 (36.5) 69 (35.9) 22 (38.6) 0.755
Paradoxical upgrading reaction 37 (14.9) 20 (10.4) 17 (29.8) 0.001
Ethnicity 0.039
African 27 (10.8) 18 (9.4) 9 (15.8)
Middle Eastern 2 (0.8) 1 (0.5) 1 (1.8)
South East Asian 11 (4.4) 10 (5.2) 1 (1.8)
South Asian 149 (59.8) 110 (57.3) 39 (68.4)
White European 60 (24.1) 53 (27.6) 7 (12.3)
Clinic site ,0.001
A 104 (41.8) 97 (50.5) 7 (12.3)
B 62 (24.9) 38 (19.8) 24 (42.1)
C 53 (21.3) 42 (21.9) 11 (19.3)
D 30 (12.0) 15 (7.8) 15 (26.3)
Baseline blood results, median [IQR]†
Lymphocytes 3109/l 1.4 [1.02–1.90] 1.4 [1.04–1.90] 1.34 [0.97–1.82] 0.592
Monocytes 3109/l 0.6 [0.43–0.80] 0.61 [0.50–0.80] 0.56 [0.40–0.80] 0.177
Neutrophils 3109/l 4.5 [3.40–6.08] 4.55 [3.40–5.90] 4.41 [3.38–6.78] 0.665
Haemoglobin 3109/l 130 [115–140] 130 [116–141] 125 [111–137] 0.223
ESR, mm/h 29 [13–51] 33 [13–50] 27 [10–61] 0.944
Albumin, g/l 34 [30–38] 35 [30–38] 33 [28–37] 0.131
CRP, mg/l 23 [5–65] 21 [5–65] 29 [6–65] 0.505
25-hydroxycholecalciferol, nmol/l, 10 [LDL–19.0] 16 [LDL–26.0] LDL [LDL–10.0] 0.004
Sites of TB disease
Pleural 48 (19.3) 39 (20.3) 9 (15.8) 0.567
Central adenopathy 134 (53.8) 103 (53.6) 31 (54.4) 1
Peripheral adenopathy 96 (38.6) 70 (36.5) 26 (45.6) 0.219
Central nervous system 6 (2.4) 4 (2.1) 2 (3.5) 0.623
Bone or joint 36 (14.5) 21 (10.9) 15 (26.3) 0.009
Pericardial 9 (3.6) 6 (3.1) 3 (5.3) 0.433
Abdominal 47 (18.9) 34 (17.7) 13 (22.8) 0.441
Miliary 2 (0.8) 1 (0.5) 1 (1.8) 0.406
Other 22 (8.8) 17 (8.9) 5 (8.8) 1
Microbiology or histology-confirmed diagnosis‡ 222 (89.2) 167 (87.0) 55 (96.5) 0.051
More than one site of TB disease§ 96 (38.6) 70 (36.5) 26 (45.6) 1
Baseline steroid 54 (21.7) 42 (21.9) 12 (21.1) 1
Other immunomodulatory drug¶ 11 (4.4) 10 (5.2) 1 (1.8) 0.465
Adverse drug reaction recorded 67 (26.9) 52 (27.1) 15 (26.3) 0.864
Hypercalaemia before TB diagnosis 15 (6.0) 14 (7.3) 1 (1.8) 0.203
Hypocalaemia before TB diagnosis 7 (2.8) 4 (2.1) 3 (5.3) 0.362
Calcaemia during anti-tuberculosis treatment 0.879
Hypercalcaemic 10 (4.0) 7 (3.6) 3 (5.3)
Hypocalcaemia 4 (1.6) 3 (1.6) 1 (1.8)
Normocalcaemic 192 (77.1) 144 (75.0) 48 (84.2)
Not recorded 43 (17.3) 38 (19.8) 5 (8.8)
*All tests were Fisher’s exact test (categorical variables) or Wilcoxon rank-sum (numerical variables).
† Availability of baseline blood results: 222/249 had full blood; 209/249 had CRP; 226/249 had albumin; 113 had ESR; and 93/249 had vitamin D level available.
‡ Diagnostic sample (e.g., fine-needle aspiration) was AFB-positive on microscopy, grewM. tuberculosis on culture or showed features consistent with TB disease
on cytology or histology diagnosis.
§More than one of the following disease sites: pleural; central adenopathy, peripheral adenopathy, any intra-abdominal disease, pericardial, central nervous
system, bone or joint, skin or eye. Miliary diagnosis automatically classified as .1 site.
¶ Included disease-modifying anti-rheumatic drugs and interferon therapy.
IQR¼ interquartile range; ESR¼erythrocyte sedimentation rate; CRP¼C-reactive protein; LDL¼ lower than the limit of detection; TB¼ tuberculosis; AFB¼acid-fast
bacilli.
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Univariate associations with a paradoxical upgrading
reaction
Variables associated with a PUR on univariate testing
were lower age, the clinic site where treatment was
given, lower lymphocyte count, having an AFB-
positive diagnostic sample at baseline, having more
than one site of TB disease at baseline and being
prescribed vitamin D during anti-tuberculosis treat-
ment (Table 2).
Multivariate associations with a paradoxical upgrading
reaction
Although ethnicity was not significantly associated
with a PUR (P ¼ 0.374), it was considered to be a
potential confounder because prescribing of vitamin
D was influenced by patient ethnicity (Table 1, P ¼
0.039). The association between prescription of
vitamin D and a PUR was adjusted for ethnicity in a
logistic regression model, and remained significant,
with an odds ratio (OR) of 3.35 (95%CI 1.59–7.06, P
¼ 0.001; see Appendix http: / / rpubs.com/
davidadambarr/EPTB-PUR-VitD). When the ethnici-
ty variable was collapsed into three categories—white
European, African, Asian (including Middle Eastern,
South East Asian and South Asian) due to low
frequencies in some of the pre-specified ethnic
categories—prescription of vitamin D was associated
with a higher rate of PUR in each grouping (Figure A).
The clinic site was also considered an important
potential confounder because clinics had different
rates of vitamin D prescribing and different rates of
observed PURs. Clinic C was found to be an outlier
with much lower rates of vitamin D prescribing and
PUR than the other sites. Only 11/53 (21%) of
patients at clinic C were prescribed vitamin D, and
none had an observed PUR (Figure B). This ‘zero
frequency cell’ in a contingency table of a PUR by
clinic site and vitamin D prescription meant that
clinic site could not be included in a full multivariate
model. Instead, an exact logistic regression model17
was performed to adjust vitamin D prescription for
clinic site. In this model, vitamin D prescription
remained significant, with an OR of 3.70 (95%CI
1.54–13.23, P , 0.001; see Appendix http://rpubs.
com/davidadambarr/EPTB-PUR-VitD). In addition,
each patient prescribed vitamin D was matched with
a control using a propensity score for vitamin D
prescription based on all the variables associated with
vitamin D prescription and a PUR (clinic site, age and
ethnicity). In this analysis, patients prescribed vitamin
Table 2 Univariate associations with a PUR
No PUR
(n ¼ 212)
PUR
(n ¼ 37) P value*
Age, years, median [IQR] 38.1 [30.0–52.8] 30 [23.5–42.3] 0.002†
Female 81 (38.2) 10 (27.0) 0.267
Prescribed vitamin D 40 (18.9) 17 (45.9) 0.001†
Ethnicity 0.374
African 21 (9.9) 6 (16.2)
Middle Eastern 2 (0.9) 0 (0.0)
South East Asian 9 (4.2) 2 (5.4)
South Asian 125 (59.0) 24 (64.9)
White European 55 (25.9) 5 (13.5)
Clinic site 0.009*
A 92 (43.4) 12 (32.4)
B 49 (23.1) 13 (35.1)
C 50 (23.6) 3 (8.1)
D 21 (9.9) 9 (24.3)
Baseline blood results, median [IQR]
Lymphocytes 3109/l 1.43 [1.10–1.90] 1.14 [0.83–1.51] 0.013†
Monocytes 3109/l 0.6 [0.47–0.80] 0.66 [0.40–0.81] 0.649
Neutrophils 3109/l 4.48 [3.40–5.93] 4.95 [3.35–6.62] 0.696
Haemoglobin, g/l 130 [116–141] 124 [114–137] 0.306
ESR, mm/h 29 [13–49] 33 [10–61] 0.609
Albumin, g/l 34 [30–38] 34 [29–38] 0.641
CRP, mg/l 20 [5–55] 55 [13–73] 0.045†
25-hydroxycholecalciferol, nmol/l 10 [LDL–20] LDL [LDL–10] 0.219
More than one site of TB disease‡ 76 (35.8) 20 (54.1) 0.044†
Diagnostic sample AFB-positive 60 (28.3) 20 (54.1) 0.004†
Diagnostic sample culture-positive 125 (59.0) 28 (75.7) 0.067
Baseline steroid 42 (19.8) 12 (32.4) 0.128
Other immunomodulatory drug§ 11 (5.2) 0 0.377
*All tests were Fisher’s exact test (categorical variables) or Wilcoxon rank-sum (numerical variables).
† Significant (P , 0.05).
‡More than one of the following disease sites: pleural; central adenopathy, peripheral adenopathy, any intra-abdominal
disease, pericardial, central nervous system, bone or joint, skin or eye. Miliary diagnosis automatically classified as .1
site.
§ Included disease-modifying anti-rheumatic drugs and interferon therapy.
PUR ¼ paradoxical upgrading reaction; IQR ¼ interquartile range; ESR ¼ erythrocyte sedimentation rate; CRP ¼ C-
reactive protein; LDL¼ lower than limit of detection; TB¼ tuberculosis; AFB¼ acid-fast bacilli.
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D remained at greater risk for a PUR than propensity
score-matched controls (OR 2.60, 95%CI 1.04–6.96,
P ¼ 0.046; see Appendix http://rpubs.com/
davidadambarr/EPTB-PUR-VitD).
Finally, to create a multivariate model, all variables
found to be significant on univariate testing except
the clinic site were used. Ethnicity was also included
as a potential confounder. In this ‘full’ model,
younger age, an AFB-positive diagnostic sample,
lymphocyte count and vitamin D prescription had
largely unchanged OR estimates (Table 3). A more
parsimonious model with variables deselected step-
wise based on the Akaike Information Criterion was
found to have equivalent fit and predictive perfor-
mance. This model retained age, AFB status of the
diagnostic sample, lymphocyte count, multiple sites
of TB disease at baseline and vitamin D prescription
as important independent variables (Table 3).
DISCUSSION
This is the first cohort study to examine the
relationship between use of vitamin D and the risk
of a PUR. We found a significant independent
increased risk of a PUR to be associated with younger
age, AFB positivity of the diagnostic sample, lym-
phopaenia, multiple sites of TB disease and receipt of
vitamin D supplementation at baseline.
Younger age2,4,18–20 and lower lymphocyte
count5,19,21,22 at the time of the TB diagnosis have
been identified as risk factors for a PUR in previous
cohort studies, and are mechanistically plausible
mediators of the host immune response in a PUR.
We also found having an AFB-positive diagnostic
sample and multiple sites of TB disease at diagnosis to
be risk factors for a PUR. Patients in this cohort were
extensively investigated—92% underwent invasive
sampling to attempt a microbiological or histological
diagnosis before treatment—thereby reducing the risk
of bias in these estimates. Several studies have found
more extensive disease at baseline to be a risk
factor,3,18,22 and a trend towards higher PUR in
AFB-positive cases has also been described.1 More
extensive disease and AFB-positive diagnostic sample
variables suggest that a higher baseline antigen load is
related to PUR development.
The active metabolite, 1a,25-dihydoxy vitamin D
(1a,25(OH)2D3), supports an innate pro-inflamma-
tory TLR-associated macrophage response in vitro, a
response necessary for effective intracellular myco-
bacterial killing.23 Pre-treatment of monocytes with
1a,25(OH)2D3 induces cellular maturation and
increased production of the innate cytokine tumour
necrosis factor following lipopolysaccharide stimula-
tion via TLR4 signalling.24 Mycobacterial stimula-
tion of TLR1/2 on monocytes also leads to enhanced
expression of the vitamin D receptor and 1a-
hydroxylase CYP27B1 and, in the presence of
sufficient vitamin D, leads the antimicrobial activity
via cathelicidin production.23 Enhancement of TLR
signalling by supplementation with vitamin D in a
patient with deficiency of vitamin D could therefore
plausibly cause an upgraded innate immune response
analogous to that seen in TB-IRIS.
Figure A) Patient ethnicity and B) clinic site as possible confounders of association between
vitamin D and a paradoxical upgrading reaction. Error bars are standard errors for the proportion
based on binomial probability distribution. *No prescription of vitamin D during anti-tuberculosis
treatment. †Vitamin D supplement prescribed during anti-tuberculosis treatment.
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Conversely, the effects of vitamin D on the adaptive
immune system are thought to be anti-inflammatory,
driving FoxP3 and CTLA4 expression, markers of
regulatory T (Treg) cells and promoting type 2 T
helper (Th2) cells, and blocking production of pro-
inflammatory cytokines interleukin (IL) 2, IL-17 IL-
21 and interferon-gamma.25,26 However, these ob-
servations vary according to the timing of treatment,
the differentiation status of the vitamin D-treated
cells and the presence of microbial products during
treatment. Naı¨ve CD4þ T-cells treated with active
vitamin D suppress IL-4 production (the hallmark of
Th2 cells), whereas co-treatment of CD4þ and CD8þ
T cells with 1a,25(OH)2D3 and IL-4 induces IL-6
production.26,27
Thus, vitamin D supplementation, depending on
immune status and degree of antigen load,28 might
just as much uncover or exacerbate pathological
immune imbalances specific to some TB-susceptible
hosts as it may prevent or resolve them. We speculate
that supplementation of at-risk patients with high
antigen load may lead to exacerbation of the innate
TLR-mediated response, leading to exacerbated
innate cytokine signalling similar to that observed in
TB-IRIS. This response is also analogous to a reversal
reaction in leprosy (progression from lepromatous to
tuberculoid leprosy), and is associated with a switch
in the inflammatory balance from phagocytic to
vitamin D-mediated antimicrobial macrophage func-
tion and clearance of mycobacteria.29 A reversal
reaction is also associated with increased FoxP3
staining in lesions,30 consistent with the role of
vitamin D in Treg differentiation, as well as influx
of Th1 cells.31
The activation of the innate response by vitamin D
primarily induces antimicrobial responses; a PUR
could be associated with improved clearance of
bacteria, but at the cost of increased inflammatory
disease. This hypothesis suggests that the role of host-
directed therapies (HDTs) such as vitamin D should
be defined according to the specific clinical problem
they are intended to solve, and that their effects may
differ across the spectrum of TB disease and host
response. Reassuringly, and as shown previously, a
PUR was not associated with a high risk of serious
adverse outcomes in our cohort, but did cause
significant morbidity for some patients. Microbio-
logical failure rates in EPTB cannot be routinely
determined, but failures in clinical treatment or
relapses in our low HIV, low multidrug-resistant TB
setting were ,2%. To gain maximum utility from
future HDTs, knowing which patients can benefit
from enhanced bactericidal activity and which could
benefit from anti-inflammatory therapy is necessary.
Weaknesses of this study stem from its retrospec-
tive design. The definition of a PUR had to be applied
retrospectively due to differences between treating
clinicians in how formally these cases were diag-
nosed. Inter-rater agreement was, however, strong
despite this limitation. The four clinic sites used in
this study had markedly different patient character-
istics. However, as the clinic site could not be
included in the final multivariate modelling due to
the low frequency of events and vitamin D prescrip-
tion at one clinic, this potential confounding could
not be addressed fully. Finally, too few patients had
serial serum levels of vitamin D checked to allow
direct analyses of dose–concentration and PUR-
response relationships, which would have provided
a more robust test of a causal relationship between
vitamin D and PURs, as would the measurement of
vitamin D-associated inflammatory markers.
CONCLUSIONS
The PUR phenomenon is further evidence that,
despite our current standardised approach to treat-
ment, TB disease exists in a spectrum of host–
Table 3 Logistic regression results for associations with a PUR*
Variable
Univariate model Full model Final model
OR (95%CI) P value† OR (95%CI) P value† OR (95%CI) P value†
Vitamin D prescription 3.66 (1.75–7.62) 0.001 3.43 (1.53–7.69) 0.003 3.28 (1.31–8.22) 0.011
AFB-positive diagnostic sample 2.98 (1.46–6.14) 0.003 3.04 (1.40–6.72) 0.005 3.73 (1.57–9.25) 0.003
log(age, years) 0.22 (0.08–0.57) 0.003 0.23 (0.07–0.72) 0.013 0.10 (0.02–0.34) 0.001
log(lymphocytes, 3109/l þ 1) 0.24 (0.06–0.72) 0.014 0.25 (0.06–1.11) 0.072 0.10 (0.02–0.58) 0.012
Multiple sites of TB disease 2.11 (1.04–4.30) 0.038 1.65 (0.75–3.64) 0.209 2.30 (0.95–5.70) 0.067
Log (CRP, mg/l þ1) 1.28 (0.98–1.69) 0.080 1.06 (0.78–1.46) 0.700 — —
Ethnicity White European 0.45 (0.15–1.11) 0.110 0.95 (0.27–2.95) 0.929 — —
*Non-normally distributed age, CRP and lymphocyte count were log-transformed before inclusion.
† Based on the Wald test on variable coefficient: univariate models were logistic regressions predicting a PUR from one independent variable; the full model
included ethnicity plus all variables found to be significant in univariate testing (from Table 2) except the clinic site, which could not be included due to a zero cell in
the contingency table. The full model had a2log likelihood (comparing this model to a null model) v2¼36.5 on seven degrees of freedom, giving P¼5.80e-06;
AIC¼ 189; Nagelkerke pseudo R2¼24.0; predicted probabilities ROC AUC¼0.78 for a PUR outcome (within the same dataset). The final model was derived by
excluding seven cases with Cook’s distance.4 standard deviations (presumed over-influential cases), then rerunning the full model as described above, and finally
applying a stepwise backwards variable selection algorithm based on AIC. The final model had had a2log likelihood (comparing this model to the null model) v2¼
45.9 on five degrees of freedom, giving P¼ 9.72e-09; AIC¼ 147.5; Nagelkerke pseudo R2¼ 32.7; predicted probabilities ROC AUC¼ 0.84 for a PUR outcome
(within the same dataset).
PUR ¼ paradoxical upgrading reaction; OR ¼ odds ratio; CI ¼ confidence interval; AFB ¼ acid-fast bacilli; CRP ¼ C-reactive protein; AIC ¼ Akaike Information
Criterion; ROC¼ receiver operating characteristic; AUC¼ area under the ROC curve.
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pathogen interactions. We should anticipate that the
effects of future HDTs may be stratified by patient
variables such as age, vitamin D status, lymphocyte
count, antigenic load and inflammatory status. Most
importantly, our results highlight that future trials of
HDTs should consider adequate powering to detect
PUR outcomes and prospectively define patient
subgroups who may respond differently to these
novel therapies.
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Table A.2 Definitions of variables in raw data
Variable Definition
DAB Index for a PUR diagnosis by reviewer DAB; PUR ¼ probable or definite PUR, No_PUR ¼ unlikely or no PUR
RAS Index for a PUR diagnosis by reviewer RAS; PUR ¼ probable or definite PUR, No_PUR ¼ unlikely or no PUR
DJB Index for a PUR diagnosis by reviewer DJB; PUR ¼ probable or definite PUR, No_PUR ¼ unlikely or no PUR
PUR PUR ¼ minimum 2/3 reviewers classified as a PUR; No_PUR ¼ maximum one reviewer classified as a PUR
PUR.date Date of a PUR diagnosis (not date of symptom onset)
PUR.Rx Any treatment prescribed for PUR management
Ethnicity As recorded in clinical notes, and classified by study authors into five categories: South Asian, White European,
sub-Saharan African, South-East Asian, West Asian (Middle East, including North African and Eastern
Mediterranean). In some cases where ethnicity was not recorded in the clinical notes, but country of origin for
first-generation immigrants to Scotland was, the latter was used as a proxy
Clinic Patients included in the cohort were recruited from four Glasgow centres treating TB cases, designated A, B, C,
and D here. All are tertiary hospitals providing in-patient and out-patient TB care
Pleural Yes/no: pleural disease diagnosed by clinicians responsible for patient’s care at the time of the TB diagnosis
Internal.LN Yes/no: intra-thoracic and/or intra-abdmominal lymph node disease identified at the time of the TB diagnosis on
imaging studies
External.LN Yes/no: extra-thoracic/extra-abdominal (i.e., cervical, auxillary, etc) lymph node disease diagnosed by clinicians
responsible for patient’s care at the time of the TB diagnosis on clinical examination or imaging studies, 6
histological or microbiological evidence
CNS Yes/no: disease in the central nervous system diagnosed by clinicians responsible for patient’s care at the time of
the TB diagnosis
BJI Yes/no: bone or joint disease diagnosed by clinicians responsible for patient’s care at the time of the TB diagnosis
Pericardial Yes/no: pericardial disease diagnosed by clinicians responsible for patient’s care at the time of the TB diagnosis
Abdominal Yes/no: intra-abdominal disease (including genito-urinary, liver, spleen, gastro-intestinal tract sites) diagnosed by
clinicians responsible for patient’s care at the time of the TB diagnosis
Miliary Yes/no: miliary disease diagnosed by clinicians responsible for patient’s care at the time of the TB diagnosis
Other.site Yes/no: any other site of disease diagnosed (including skin, eyes) by clinicians responsible for patient’s care at the
time of the TB diagnosis
Microscopy.diagnosis positive/negative: acid-fast bacilli identified in any clinical sample taken pre-treatment
Culture.diagnosis positive/negative: a clinical sample taken pre-treatment that grew M. tuberculosis upon culture
Histology.diagnosis positive/negative: a biopsy or cytology sample showed evidence of TB infection (including any granulomatous
inflammation)
Basis.diagnosis ‘micro_or_histo_confirmed’ if positive microscopy, culture or histology as defined above; otherwise
‘clinical_diagnosis’
Baseline.steroid Yes/no: patient was started on corticosteroid therapy at the same time as anti-tuberculosis treatment was initiated
Other.immuno.drug Yes/no: patient taking any of the following during anti-tuberculosis treatment: oncological chemotherapy,
interferon therapy, anti-inflammatory DMARDs or any monoclonal antibody preparation
Lymphocytes Lymphocyte count at baseline (61 week of TB treatment start date), 109/l
Monocytes Monocytes count at baseline (61 week of TB treatment start date), 109/l
Neutrophils Neutrophil count at baseline (61 week of TB treatment start date), 109/l
Haemoglobin Haemoglobin concentration at baseline (61 week of TB treatment start date), g/dl
ESR ESR at baseline (62 week of TB treatment start date), mm/h
Albumin Albumin count at baseline (61 week of TB treatment start date), g/l
CRP CRP concentration at baseline (61 week of TB treatment start date), mg/l
Prior.hypercalcaemia Any adjusted calcium level greater than local reference range recorded in the 3 months before starting anti-
tuberculosis treatment
Prior.hypocalcaemia Any adjusted calcium level less than local reference range recorded in the 3 months before starting anti-
tuberculosis treatment
Calcaemia_during.TBRx Any adjusted calcium level greater than local reference range during TB treatment ¼ hypercalcaemia; any adjusted
calcium level less than local reference range during anti-tuberculosis treatment ¼ hypocalcaemia; if blood
calcium was not checked during anti-tuberculosis treatment ¼ NA
vitD.baseline Vitamin D level at the time of initiation of TB treatment, 63 months, in nmol/l
vitD.6mths Vitamin D level 6 months after initiation of TB treatment, 63 months, in nmol/l
vitD.12mths Vitamin D level 12 months after initiation of TB treatment, 63 months, in nmol/l
vitD.Rx Vitamin D supplement started (new prescription recorded) during anti-tuberculosis treatment ¼ VitD.Rx
vitD.dose Equivalent to 6800 IU colecalciferol per day (e.g., AdCal D3, one tablet b.d.) ¼ low; .800 IU colecalciferol per
day ¼ high
ADR ADR_recorded ¼ any adverse drug reaction recorded in discharge summaries, referral letters or clinic letters
Date.TB.Rx.start Date of first dose of anti-tuberculosis chemotherapy
Date.TB.Rx.finish Date of first dose of anti-tuberculosis chemotherapy
VitD.Rx.Date Date of first vitamin D prescription during anti-tuberculosis treatment
age Age at the TB diagnosis
PUR ¼ paradoxical upgrading reaction; TB ¼ tuberculosis; DMARD ¼ disease-modifying anti-rheumatic drug; ESR ¼ erythrocyte sedimentation rate; CRP ¼ C-
reactive protein; NA¼ not available; IU¼ international unit; ADR¼ adverse drug reaction.
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R E S U M E
OB J E C T I F S : Les re´actions paradoxales a` la tuberculose
(TB) sont un exemple notable de notre compre´hension
incomple`te de l’interaction hoˆte pathoge`ne pendant le
traitement de la TB. Nous avons voulu de´terminer les
facteurs de risque de re´action paradoxale a` la TB et
spe´cifiquement e´valuer une association inde´pendante
avec la prescription de vitamine D.
S CH E´MA : Des patients adultes conse´cutifs ne´gatifs a`
l’infection pour le virus de l’immunode´ficience humaine
(VIH) traite´s pour une TB extrapulmonaire ont e´te´
identifie´s a` partir d’une base de donne´es de Surveillance
Etendue des Infections a` Mycobacte´ries. Dans notre
contexte, la vitamine D est prescrite de manie`re variable
aux patients TB nouvellement diagnostique´s. Une
de´finition pre´ce´demment publie´e des re´actions
paradoxales a` la TB a e´te´ re´trospectivement applique´e
aux dossiers e´lectroniques centralise´s des patients et les
donne´es de tous les facteurs de risque pre´ce´demment
de´crits ont e´te´ extraites de ces dossiers. L’association de
la prescription de vitamine D a e´te´ e´value´e par re´gression
logistique multivariable.
R E´ S U LTAT S : La majorite´ des 249 patients inclus avait
des ade´nopathies TB ; 222/249 avaient une TB
confirme´e par microbiologie et/ou par histologie. La
vitamine D a e´te´ prescrite a` 57/249 (23%) patients ; 37/
249 (15%) ont e´te´ classe´s comme ayant des re´actions
paradoxales. Les facteurs de risque inde´pendants trouve´s
ont e´te´ le jeune aˆge, un e´chantillon positif aux bacilles
acido-alcoolo-re´sistants, de multiples sites de maladie,
une nume´ration de lymphocytes plus faible et la
prescription de vitamine D.
C O N C L U S I O N : Nous spe´culons que les cellules
immunitaires pro-inflammatoires inne´es me´die´es par la
vitamine D, avec une charge antige´nique e´leve´e,
pourraient eˆtre a` l’origine des re´actions paradoxales
pendant le traitement de la TB.
R E S UM E N
MARCO DE R E F E R ENC I A: La ciudad de Glasgow en
Escocia, en el Reino Unido.
OB J E T I V O S: La reaccio´n parado´jica al tratamiento
antituberculoso representa un claro ejemplo de la
deficiencia de los conocimientos sobre las interacciones
entre el agente pato´geno y el hospedero durante el
tratamiento de la tuberculosis (TB). El estudio busco´
determinar los factores de riesgo de aparicio´n de la
reaccio´n parado´jica y examinar de manera especı´fica
una asociacio´n con la administracio´n de vitamina D.
M E´ TODO: Se escogieron de la base de datos de la
vigilancia ampliada de las infecciones por micobacterias
los pacientes adultos consecutivos, negativos frente al
virus de la inmunodeficiencia humana (VIH), tratados
por TB extrapulmonar. En este entorno se receta de
manera variable la vitamina D a los pacientes con
diagno´stico reciente de TB. Se utilizo´ la definicio´n de
reaccio´n parado´jica al tratamiento antituberculoso
publicada en un artı´culo anterior y se extrajeron de las
historias clı´nicas informa´ticas centralizadas los datos
relacionados con todos los factores de riesgo conocidos.
Mediante un ana´lisis de regresio´n logı´stica se evaluo´ el
efecto de la administracio´n de vitamina D.
R E S U LTA D O S: Se incluyeron en el estudio 249
pacientes; la mayorı´a presento´ adenopatı´a tuberculosa;
en 222/249 casos hubo confirmacio´n microbiolo´gica o
patolo´gica del diagno´stico de TB. Se receto´ la vitamina
D a 57/249 pacientes (23%) y se diagnostico´ la reaccio´n
parado´jica en 37 casos (15%). Los factores de riesgo
independientes revelados por el estudio fueron una edad
ma´s temprana, la presencia de bacilos acidorresistentes
en una muestra obtenida mediante una te´cnica cruenta,
la enfermedad con localizaciones mu´ltiples, un recuento
ma´s bajo de linfocitos y la administracio´n de vitamina D.
C O N C L U S I O´ N: Se formula la hipo´tesis de que la
vitamina D actu´a como mediador de la sen˜alizacio´n
celular de la inmunidad innata proinflamatoria y que,
asociada con una gran carga antige´nica, puede participar
en las reacciones parado´jicas durante el tratamiento
antituberculoso.
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